FDA orders J&J to cite death risks with taking Natrecor

04/26/2005 | NYTimes.com

Johnson & Johnson is changing the packaging insert for its heart failure drug, Natrecor, to state an increased risk of death associated with the medicine. The firm acted on orders from the FDA that notified Scios, J&J's subsidiary that makes the drug, that the information intended for professionals needed to be revised, citing at least seven published journal studies.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT